{"id":61679,"date":"2026-05-07T14:19:38","date_gmt":"2026-05-07T14:19:38","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/61679\/"},"modified":"2026-05-07T14:19:38","modified_gmt":"2026-05-07T14:19:38","slug":"dr-reddys-nestle-india-jv-launches-drug-to-address-nutrition-gaps-and-preserving-muscle-health-among-diabetic-obesity-patients-on-glp-1-therapy","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/61679\/","title":{"rendered":"Dr Reddy’s-Nestl\u00e9 India JV launches drug to address nutrition gaps and preserving muscle health among diabetic, obesity patients on GLP-1 therapy"},"content":{"rendered":"

Dr. Reddy\u2019s and Nestl\u00e9 Health Science Ltd., a joint venture between
\n Dr. Reddy\u2019s Laboratories Ltd.
\n <\/a> and
\n Nestl\u00e9 India Ltd.
\n <\/a>, has launched Celevida GLP+, a nutritional supplement aimed at ensuring optimum nutrition intake and maintaining muscle mass in people undergoing GLP-1\/GIP therapy for the management of type 2 diabetes and obesity in India.<\/p>\n

The launch comes close to the patent expiry of one of the global blockbuster GLP-1 drug semaglutide and introduction of low cost generic versions of the drug in the Indian market.<\/p>\n

According to the company, Celevida\u00a0GLP+ has been\u00a0scientifically designed and co-created with leading endocrinologists and diabetologists to\u00a0address protein gaps and preserve muscle mass and function in individuals undergoing GLP-1\/GIP therapy. It is formulated using fast-absorbing whey protein isolate (WPI), known to be gentle on the gut and suitable during periods of gastrointestinal intolerance commonly associated with GLP-1\/GIP therapy.\u00a0<\/p>\n

\u00a0“GLP-1 therapies represent a significant advancement in diabetes and obesity management. However, a clear unmet need remains in supporting patients beyond pharmacological treatment, particularly in addressing nutrition gaps and preserving muscle health during therapy,” says M.V. Ramana, CEO, Global Generics\u00a0at\u00a0Dr.\u00a0Reddy’s\u00a0Laboratories Ltd. and Director, Dr. Reddy’s and Nestl\u00e9 Health Science Ltd. <\/p>\n

“As patients experience changes in body composition, ensuring adequate nutrient intake and maintaining lean body mass becomes critical to sustaining long-term outcomes. With Celevida\u00a0GLP+, we aim to address this gap through a targeted, science-backed nutritional solution that complements pharmacological therapies and supports better overall patient outcomes in their everyday journey. As part of this commitment, we remain focused on advancing integrated, patient-centric solutions that enable more sustainable and holistic management of metabolic health,” he adds.<\/p>\n

Celevida\u00a0GLP+ provides 48 g of protein per 100 g, along with 100% RDA (Recommended Dietary Allowance) of branched-chain amino acids (BCAAs). It also provides 27 essential nutrients, including vitamins A, D and calcium.<\/p>\n

Dr. Reddy\u2019s and Nestl\u00e9 Health Science already have an established presence in specialised nutrition for people with diabetes through Celevida Diabetes Nutrition, which is designed to support comprehensive diabetes management.<\/p>\n

Celevida\u00a0GLP+ is available in a 350 g pack across pharmacies, retail outlets, and leading e-commerce platforms.<\/p>\n

Hyderabad-based Dr. Reddy\u2019s and Nestl\u00e9 Health Science Ltd. is focused on broadening its product range across various segments, including metabolic health, hospital nutrition, general wellness, women\u2019s health, and child nutrition.<\/p>\n","protected":false},"excerpt":{"rendered":"Dr. Reddy\u2019s and Nestl\u00e9 Health Science Ltd., a joint venture between Dr. Reddy\u2019s Laboratories Ltd. and Nestl\u00e9 India…\n","protected":false},"author":2,"featured_media":61680,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[126],"tags":[33983,33971,33978,33970,33977,33984,33980,199,200,33986,33979,17678,33981,33985,33973,33982],"class_list":{"0":"post-61679","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-nestle","8":"tag-bcaa-nutrition","9":"tag-celevida-glp","10":"tag-diabetes-nutrition","11":"tag-dr-reddys","12":"tag-glp-1-therapy","13":"tag-metabolic-health","14":"tag-muscle-health","15":"tag-nestle","16":"tag-nestle-india","17":"tag-nutrition-gaps","18":"tag-obesity-management","19":"tag-patient-outcomes","20":"tag-protein-supplement","21":"tag-semaglutide-generics","22":"tag-type-2-diabetes","23":"tag-whey-protein"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116533733962330753","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/61679","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=61679"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/61679\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/61680"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=61679"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=61679"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=61679"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}